Treatment Efficacy Clinical Trial
Official title:
Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock
The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU
it is Prospective randomized controlled study on One hundred forty patients to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU, Initially, each patient will be evaluated for septic shock based on the clinical criteria. Baseline microbiologic specimens will be obtained for all recruited patients through the day of diagnosis including blood C&S. Then, empirical treatment with antibiotics according to expected source of sepsis. Patients with Gram-positive cultures sensitive to Linezolid will be randomly allocated to receive Linezolid in the continuous infusion group (Group A) or conventional intermittent infusion group (Group B) in a 1:1 ratio. Group A: seventy Patients in the continuous infusion group will receive an intravenous loading dose of 600 mg for 60 min, followed by a continuous infusion of 1200 mg/day (50 mg/h). Group B: seventy patients in the intermittent infusion group will administrate 600 mg of linezolid IV every 12 h for 60 min. The treatment period will be 8-10 days in both groups but might decrease or increase based on the patients' clinical response. At the beginning of the study, simple randomization will be used to assign patients using the random numbers set offered by the ICU coordinator. Each patient will be assigned a randomized code consisting of two letters that indicate the intensive care unit and two digits indicating the randomization sequence. The end point of the study is occurrence of thrombocytopenia (decrease in platelet count ≥ 50% from baseline or a decrease in platelet count ≤ 100 × 103/mm3). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04508803 -
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT05087381 -
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
|
Phase 4 | |
Active, not recruiting |
NCT02551523 -
Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection
|
Phase 2 | |
Recruiting |
NCT06221722 -
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
|
||
Terminated |
NCT03503968 -
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06460883 -
Effects of Eccentric Banded Leg Curls Versus Eccentric Cable Leg Curls Exercises in Cricket Players
|
N/A | |
Completed |
NCT02572947 -
A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients
|
Phase 2 | |
Completed |
NCT05144295 -
Lubiprostone for Functional Constipation in the Under 18 Years Patients
|
Phase 3 | |
Completed |
NCT03345160 -
Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study
|
Phase 2 |